Sung-Soo Park

Daewoong Pharmaceutical is a leading South Korean healthcare company focused on the research, development, and manufacturing of globally competitive pharmaceuticals. Led by CEO Sung-soo Park, the company has a diverse portfolio spanning metabolic diseases, gastrointestinal disorders, and aesthetics, notably its botulinum toxin product Nabota. Daewoong is actively expanding its pipeline into high-growth areas such as long-acting obesity treatments and idiopathic pulmonary fibrosis therapies. The company operates extensive R&D and manufacturing facilities globally, including sites in Indonesia, China, and the United States, and is known for its strong focus on open collaboration and international partnerships.